Piper Sandler analyst Kelsey Goodwin initiated coverage of Oric Pharmaceuticals (ORIC) with an Overweight rating and $22 price target The company’s ORIC-944 is a potential best-in-class PRC2 inhibitor capable of becoming a standard of care treatment class in prostate cancer, the analyst tells investors in a research note. Piper believes the ORIC-944 clinical update in Q1 “is likely to represent a value creation event.”
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORIC:
- Oric Pharmaceuticals Highlights Promising Enozertinib Trial Results
- Oric Pharmaceuticals price target raised to $25 from $19 at Wells Fargo
- Buy Rating for Oric Pharmaceuticals: Enozertinib’s Promising Efficacy and Strategic Value
- Oric Pharmaceuticals presents data from Phase 1b trial of enozertinib
- Promising Clinical Data and Market Potential Drive Buy Rating for Oric Pharmaceuticals’ Enozertinib